Soluble E-selectin and QRISK3-based Cardiovascular Risk Assessment in Women with Polycystic Ovary Syndrome: A Prospective Case–control Study from India
Nilanchali Singh, Iman Dandapath, Akanksha Gupta, Surabhi Gupta, Rosemary Jha, Deepti Siddharthan, Ashwani Kumar Mishra, D. Kathiravan, Neeta Singh, Zakiya Zakiya
A
BSTRACT
Background:
Polycystic ovary syndrome (PCOS) is associated with metabolic abnormalities and increased long-term cardiovascular risk. Endothelial dysfunction is considered an early event in atherogenesis, and soluble E-selectin has been proposed as a marker of endothelial activation. However, its role in cardiovascular risk assessment in PCOS remains uncertain.
Aim:
The study aimed to compare circulating soluble E-selectin levels between women with PCOS and healthy controls and evaluate their association with metabolic parameters and QRISK3-based cardiovascular risk scores.
Settings and Design:
Prospective hospital-based case–control study.
Materials and Methods:
Two hundred women with PCOS diagnosed according to the Rotterdam criteria and 50 age-matched healthy controls aged 18–40 years were enrolled. Clinical assessment, anthropometry, fasting blood glucose, HbA1c, lipid profile, C-reactive protein and soluble E-selectin levels were evaluated. Estimated 10-year cardiovascular risk was calculated using the QRISK3 algorithm.
Statistical Analysis Used:
Group comparisons, correlation analyses and multivariable linear regression were performed.
Results:
Mean soluble E-selectin levels were comparable between women with PCOS and controls (0.61 ± 0.33 vs. 0.61 ± 0.29 ng/mL,
Conclusion:
Soluble E-selectin levels did not differ between women with PCOS and controls and showed limited associations with cardiovascular risk factors. These findings do not support a major role for soluble E-selectin in cardiovascular risk assessment among young women with PCOS.